# A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma

> **NCT04072900** · PHASE1 · UNKNOWN · sponsor: **Xiangya Hospital of Central South University** · enrollment: 30 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **DRUG:** Peptide
- **DRUG:** Anti-PD-1
- **DRUG:** rhGM-CSF
- **DRUG:** Imiquimod 5% Topical Cream

## Key facts

- **NCT ID:** NCT04072900
- **Lead sponsor:** Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-21
- **Primary completion:** 2021-09-01
- **Final completion:** 2022-09-01
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04072900

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04072900, "A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma". Retrieved via AI Analytics 2026-09-13 from https://api.ai-analytics.org/clinical/NCT04072900. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*